China grants licence to Merck's KEYTRUDA for stomach cancer treatment
BEIJING (Reuters) - China's National Drug Administration has granted Merck's KEYTRUDA therapy a licence for first-line treatment of certain stomach cancer patients in the country.
Merck is known as MSD outside the United States and Canada.
(Reporting by Beijing newsroom; Editing by David Goodman)